TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7866602

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitroglycerine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blocker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2768616

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate (Ritalin)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg methylphenidate (Ritalin)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 687500

Group type: EXPERIMENTAL
Intervention: Ephedrine 60 or 90 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 210 or 240 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ephedrine 60 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 210 mg
Number of subjects: 2
Study: 30962030

Group type: EXPERIMENTAL
Intervention: 2-dimensional technique
Number of subjects: 57

Group type: COMPARATOR
Intervention: 3-dimensional technique
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 57
Study: 28198583

Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tube based on the Khine formula (Group R)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cuffed endotracheal tube that was a half-size (0.5 mm ID) smaller (Group S)
Number of subjects: 100
Study: 25769746

Group type: EXPERIMENTAL
Intervention: Reduced-sodium lunches (29% to 61% sodium reduction)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Reduced-sodium lunches
Number of subjects: 74

Group type: COMPARATOR
Intervention: Regular foods (control group)
Number of subjects: 74
Study: 23377843

Group type: EXPERIMENTAL
Intervention: Common identity treatment (to enhance their sense of commonality)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (standard health information)
Number of subjects: 86
Study: 21319929

Group type: EXPERIMENTAL
Intervention: Positive attributional style condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative attributional style condition
Number of subjects: 0
Study: 19243891

Group type: EXPERIMENTAL
Intervention: Alcohol administration (0.6 g/kg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alcohol effects on prolactin, cortisol, and adrenocorticotropin stress response
Number of subjects: 48
Study: 14739421

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 0
Study: 11349340

Group type: EXPERIMENTAL
Intervention: Weekly communication for 6 months via a totally automated, computer‐based voice system.
Number of subjects: 298

Group type: COMPARATOR
Intervention: Physical activity promotion counseling (control group).
Number of subjects: 298
Study: 9009543

Group type: EXPERIMENTAL
Intervention: PPT/Rx Firm Molded Insoles with magnetic foil
Number of subjects: 34

Group type: COMPARATOR
Intervention: PPT/Rx Firm Molded Insoles without magnetic foil (Control)
Number of subjects: 34
Study: 8270918

Group type: EXPERIMENTAL
Intervention: Treatment group (antibiotic treatment for asymptomatic UTI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 20
Study: 2887520

Group type: EXPERIMENTAL
Intervention: bopindolol (1 to 4 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: atenolol (50 to 200 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: bopindolol
Number of subjects: 31

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 31
Study: 31298727

Group type: EXPERIMENTAL
Intervention: Gas Bubble Escape (GBE) sign group
Number of subjects: 50

Group type: COMPARATOR
Intervention: No Gas Bubble Escape (no GBE) sign group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups at 1 month
Number of subjects: 50
Study: 29624493

Group type: EXPERIMENTAL
Intervention: Pazufloxacin 0.6% BID (twice a day)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pazufloxacin 0.6% TID (three times a day)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pazufloxacin 0.6% QID (four times a day)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Moxifloxacin 0.5% TID (three times a day)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Gatifloxacin 0.5% TID (three times a day)
Number of subjects: 300
Study: 26847148

Group type: EXPERIMENTAL
Intervention: LC (Traditional Chinese Medicine)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (standard treatment without LC)
Number of subjects: 57
Study: 25385295

Group type: EXPERIMENTAL
Intervention: hUC‐MSC therapy with anti‐inflammatory treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (anti‐inflammatory treatment only)
Number of subjects: 23
Study: 23209076

Group type: EXPERIMENTAL
Intervention: C312M vaccination via oral, immersion, and oral plus immersion routes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C312M vaccination
Number of subjects: 0
Study: 20837585

Group type: EXPERIMENTAL
Intervention: Helmeted
Number of subjects: 70

Group type: COMPARATOR
Intervention: Actively repositioned
Number of subjects: 70
Study: 17509404

Group type: EXPERIMENTAL
Intervention: RealSeal
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Gutta-percha
Number of subjects: 26
Study: 16206349

Group type: EXPERIMENTAL
Intervention: 4 weekly HMW hyaluronan injections (O4, n = 128)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: 3 weekly HMW hyaluronan injections followed by one arthrocentesis (O3A1, n = 120)
Number of subjects: 372

Group type: COMPARATOR
Intervention: 4 arthrocenteses without injection (control group, A4, n = 124)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: 4 weekly HMW hyaluronan injections (O4)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 372
Study: 12675978

Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET) intervention
Number of subjects: 85

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 85
Study: 10789884

Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control tasks (somatically matched)
Number of subjects: 0
Study: 8814843

Group type: EXPERIMENTAL
Intervention: Contact-laser vaporization of the prostate
Number of subjects: 102

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 102
Study: 1381763

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg b.i.d.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg b.i.d.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo b.i.d.
Number of subjects: 14
Study: 6371289

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 3531851

Group type: EXPERIMENTAL
Intervention: PK10169 low-molecular-weight heparin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29803635

Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 15
Study: 27829318

Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 25707875

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (rATG, Thymoglobulin)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Daclizumab
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Overall graft survival
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Overall graft survival at 5 years with either induction therapy
Number of subjects: 227
Study: 23128528

Group type: EXPERIMENTAL
Intervention: Methylated p14ARF gene promoter
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Methylated O6‐MGMT gene promoter
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Methylation of one or more of the genes from the set p14ARF, RASSF1A and APC1A
Number of subjects: 111
Study: 20337877

Group type: EXPERIMENTAL
Intervention: Participation in the BOOST II trial
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not participating in the BOOST II trial
Number of subjects: 100
Study: 17595381

Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT) for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control group (age-matched)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT)
Number of subjects: 0
Study: 16815320

Group type: EXPERIMENTAL
Intervention: 25 mg sumatriptan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg sumatriptan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12665269

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (Fluvent) at a daily dose of 22 microg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (Becotide) at a daily dose of 400 microg
Number of subjects: 10
Study: 9716142

Group type: EXPERIMENTAL
Intervention: Captured ELISA using kistrin to measure platelet microparticles (PMP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flow cytometry
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal washed platelets (10^8)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Outdated platelets
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fresh blood from healthy donors
Number of subjects: 12

Group type: COMPARATOR
Intervention: Heparin and protamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pericardial blood
Number of subjects: 12
Study: 8110581

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2577570

Group type: EXPERIMENTAL
Intervention: Double stapling technique
Number of subjects: 110

Group type: COMPARATOR
Intervention: EEA stapler
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Hartmann procedure using stapler techniques
Number of subjects: 110
Study: 7100

Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol t.i.d.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31724168

Group type: EXPERIMENTAL
Intervention: Structured educational package
Number of subjects: 70

Group type: COMPARATOR
Intervention: Training on breastfeeding and normal delivery (Control)
Number of subjects: 70
Study: 30353843

Group type: EXPERIMENTAL
Intervention: Self-regulated learning campaign on healthy eating
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 29901379

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg, 1 tablet a day for 4 weeks, then increased to 2 tablets a day for the next 4 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (same dosing schedule as donepezil)
Number of subjects: 41
Study: 24903024

Group type: EXPERIMENTAL
Intervention: 8 weeks of physical training
Number of subjects: 21
Study: 22209127

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive writing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional writing group (combined expressive and positive writing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 0
Study: 20456105

Group type: EXPERIMENTAL
Intervention: Pads with different amounts of lotion applied; evaluated for 3 hours using the BTK protocol.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pads with AGM core; evaluated for lotion transfer.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pads with cellulose core; evaluated for lotion transfer.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical in-use study on second series of test products; evaluated for lotion transfer.
Number of subjects: 0
Study: 18513551

Group type: EXPERIMENTAL
Intervention: Capsule endoscopy after an 8-hour fasting period (Group A)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Capsule endoscopy after drinking 2 doses of 45 mL oral sodium phosphate (NaP) (Group B)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Capsule endoscopy (both groups)
Number of subjects: 129
Study: 16129742

Group type: EXPERIMENTAL
Intervention: Calcium phosphate degradable cement (Norian SRS) augmentation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Sliding screw device alone (Control)
Number of subjects: 112
Study: 12860582

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride 1500 mg with chondroitin sulfate 1200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10980853

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical therapy (antiarrhythmic drug therapy)
Number of subjects: 0
Study: 7486901

Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM) 100 mg, twice a day for 8 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 2344171

Group type: EXPERIMENTAL
Intervention: Cefonicid (one daily intravenous dose)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nafcillin (multidose)
Number of subjects: 65
Study: 7008650

Group type: EXPERIMENTAL
Intervention: Electrical current (varied for each protocol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No electrical current (control group)
Number of subjects: 60
Study: 29117996

Group type: EXPERIMENTAL
Intervention: Isolated ultrafiltration (ultrafiltration rate 13.6 ± 3.9 ml·kg⁻¹·h⁻¹)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isovolemic dialysis
Number of subjects: 8
Study: 27336191

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 300
Study: 24827902

Group type: EXPERIMENTAL
Intervention: Pegylated interferon‐lambda‐1a (Lambda)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa‐2a (alfa)
Number of subjects: 0
Study: 23010090

Group type: EXPERIMENTAL
Intervention: Titanium exposure (5 nights)
Number of subjects: 24
Study: 20237174

Group type: EXPERIMENTAL
Intervention: Strength and functional task training for 1 hour a day for 10 consecutive working days.
Number of subjects: 11
Study: 18092695

Group type: EXPERIMENTAL
Intervention: Operative treatment (percutaneous Kirschner-wiring)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conservative treatment (close reduction and immobilisation in plaster splint)
Number of subjects: 60
Study: 15946977

Group type: EXPERIMENTAL
Intervention: Vinorelbine 25 mg/m(2) on days 1 and 8 and epirubicin 60 mg/m(2) on day 1, 3 weekly for six cycles (VE)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) i.v. on day 1, 3 weekly for six cycles (AC)
Number of subjects: 451
Study: 11828245

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g x d(‐1) during 5 d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10452142

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) levels in children with brain injury
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group of healthy children
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Renin and aldosterone levels in children with brain injury
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 50
Study: 8733874

Group type: EXPERIMENTAL
Intervention: Moderate hypothyroidism induced by half-dose thyroxine replacement therapy (cutting replacement therapy in half)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard preparation (substituting triiodothyronine for thyroxine replacement over a 3-week period, then omitting hormone therapy for 3 weeks)
Number of subjects: 0
Study: 1715416

Group type: EXPERIMENTAL
Intervention: PVB, VAB-6, BVP regimen (group A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: PEB chemotherapy (group B)
Number of subjects: 34
Study: 6751239

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 29989468

Group type: EXPERIMENTAL
Intervention: Multifactorial program (exercise, medication review, and education)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 13
Study: 29205150

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidopexy (SH)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Traditional haemorrhoidectomy (TH)
Number of subjects: 777
Study: 26789749

Group type: EXPERIMENTAL
Intervention: School-based treatment (SBT) with praziquantel, coverage 84.2%.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 75
Study: 24504198

Group type: EXPERIMENTAL
Intervention: Sinusoidal linear acceleration at 30 mG
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sinusoidal linear acceleration at 1.25 mG
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sinusoidal linear acceleration at 10 mG
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sinusoidal linear acceleration at 6.5 mG
Number of subjects: 16
Study: 22970933

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of the fetal head position
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard care (transvaginal digital examination)
Number of subjects: 450
Study: 20304540

Group type: EXPERIMENTAL
Intervention: n-3 LC-PUFA-enriched dairy products (3g n-3 LC-PUFA/d)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control dairy products
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: n-3 LC-PUFA-enriched dairy products
Number of subjects: 51
Study: 17327294

Group type: EXPERIMENTAL
Intervention: Tobramycin 6 mg/kg once daily plus penicillin G 5 million IU x 4
Number of subjects: 174

Group type: COMPARATOR
Intervention: Tobramycin 6 mg/kg three times daily plus penicillin G 5 million IU x 4
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 174
Study: 16277774

Group type: EXPERIMENTAL
Intervention: High vitamin C diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low vitamin C diet
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High meat diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low meat diet
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High phytic acid diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low phytic acid diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Diet with lowest bioavailability
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Diet with highest bioavailability
Number of subjects: 32
Study: 12014534

Group type: EXPERIMENTAL
Intervention: Nurse-led screening
Number of subjects: 3001

Group type: COMPARATOR
Intervention: Prompted opportunistic case finding
Number of subjects: 3001
Study: 10467991

Group type: EXPERIMENTAL
Intervention: Low-fat milk (1.0 g fat/dl, 3.3 g protein/dl)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Standard-fat milk (3.5 g fat/dl, 3.3 g protein/dl)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Partially vegetable fat and protein-reduced milk (3.5 g fat/dl, 50% vegetable; 2.2 g protein/dl)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Full-vegetable-fat milk (3.5 g fat/dl, 100% vegetable; 3.0 g protein/dl)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Low-fat milk
Number of subjects: 38

Group type: COMPARATOR
Intervention: Milks containing vegetable fat
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 38
Study: 8316752

Group type: EXPERIMENTAL
Intervention: 50 W/6 min stage
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ramp (15 W per min)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 50 W/3 min stage
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Various exercise programmes
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Submaximal and peak oxygen consumption, peak heart rate, rate pressure product, workload and minute ventilation
Number of subjects: 11
Study: 2894993

Group type: EXPERIMENTAL
Intervention: WAL801 CL 8 mg b.d. for 15 days
Number of subjects: 10
Study: 30287714

Group type: EXPERIMENTAL
Intervention: Intraligamentary injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supraperiosteal injection
Number of subjects: 30
Study: 27080209

Group type: EXPERIMENTAL
Intervention: E6005 ointment (0.2%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 40
Study: 25281180

Group type: EXPERIMENTAL
Intervention: Google Glass
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional ultrasound
Number of subjects: 40
Study: 23011528

Group type: EXPERIMENTAL
Intervention: Average ICP during the first 48 hours of monitoring
Number of subjects: 499
Study: 20175714

Group type: EXPERIMENTAL
Intervention: Perindopril plus diuretic combination therapy
Number of subjects: 3825

Group type: COMPARATOR
Intervention: Perindopril monotherapy
Number of subjects: 3825
Study: 17910536

Group type: EXPERIMENTAL
Intervention: Strategy instruction to individuals
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Strategy instruction in small groups in a reciprocal teaching context
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intervention programme (15 weekly lessons of 1 hour each for 3 months)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: General reading comprehension ability
Number of subjects: 38
Study: 16040444

Group type: EXPERIMENTAL
Intervention: Michigan type splint
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: NTI splint
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison of both splint designs
Number of subjects: 38
Study: 12160622

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 115
Study: 10096374

Group type: EXPERIMENTAL
Intervention: finasteride 5 mg daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study: 9188359

Group type: EXPERIMENTAL
Intervention: Individualized discharge teaching plus videotape
Number of subjects: 50

Group type: COMPARATOR
Intervention: Individualized discharge teaching
Number of subjects: 50
Study: 2020339

Group type: EXPERIMENTAL
Intervention: Glucose-free acetate dialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bicarbonate dialysis
Number of subjects: 0